Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Danaher Corp., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


The valuation ratios exhibit varied trends over the observed period. Generally, ratios decreased from early 2022 through the first half of 2023, before experiencing increases into late 2023 and 2024. More recently, a slight downward trend is apparent in the latter half of the period examined.

Price to Earnings (P/E)
The Price to Earnings ratio began at 32.15 and generally declined to a low of 24.76 in September 2023. Subsequently, the ratio increased significantly, peaking at 48.49 in September 2024, before decreasing to 40.93 by December 2025. This suggests periods of both increased and decreased investor confidence in earnings.
Price to Operating Profit (P/OP)
Similar to the P/E ratio, Price to Operating Profit decreased from 26.48 in April 2022 to 20.71 by September 2022. It then showed an upward trajectory, reaching 35.64 in December 2023, followed by a decline to 31.54 in December 2025. The pattern mirrors the P/E ratio, indicating a correlation between profitability multiples and market valuation.
Price to Sales (P/S)
The Price to Sales ratio demonstrated a decrease from 6.68 to 5.63 between April 2022 and June 2023. An increase followed, peaking at 8.10 in June 2024, before receding to 6.02 by December 2025. This ratio appears less volatile than the earnings-based multiples, potentially reflecting a more stable assessment of revenue valuation.
Price to Book Value (P/BV)
Price to Book Value consistently exhibited a downward trend from 4.36 in April 2022 to 2.60 in June 2025. A slight recovery to 2.82 was observed in December 2025. This suggests a decreasing premium investors are willing to pay for the net asset value of the company over the period. It is the most consistently declining ratio of those examined.

Overall, the observed fluctuations in these ratios suggest dynamic market perceptions of the company’s value. The increases in 2023 and 2024 may reflect positive market sentiment or improved financial performance, while the more recent declines could indicate increased caution or changing market conditions.


Price to Earnings (P/E)

Danaher Corp., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net earnings attributable to common stockholders (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
EPS = (Net earnings attributable to common stockholdersQ4 2025 + Net earnings attributable to common stockholdersQ3 2025 + Net earnings attributable to common stockholdersQ2 2025 + Net earnings attributable to common stockholdersQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-earnings (P/E) ratio exhibits considerable fluctuation over the observed period, spanning from April 1, 2022, to December 31, 2025. Initial values indicate a relatively high valuation, followed by periods of both increase and decrease. A general observation suggests increased volatility in the latter half of the period.

Initial Period (Apr 1, 2022 – Dec 31, 2022)
The P/E ratio began at 32.15 and demonstrated a slight increase to 32.73 before declining to 26.65 by September 2022. A modest recovery to 25.65 was noted by the end of the year. This initial phase suggests a period of valuation adjustment, potentially influenced by market conditions or investor sentiment.
First Volatile Phase (Mar 31, 2023 – Sep 29, 2023)
The ratio increased to 29.99 in June 2023, then experienced a substantial decrease to 24.76 by September 2023. This represents a significant shift in valuation within a short timeframe, potentially linked to earnings performance or broader economic factors.
Subsequent Peak and Decline (Dec 31, 2023 – Dec 31, 2024)
A pronounced increase occurred, reaching a peak of 48.49 in September 2024, following a value of 39.09 in December 2023. This was followed by a sharp decline to 38.12 by March 2025, and then to 40.93 by the end of the observed period. This period demonstrates a high degree of investor expectation followed by a correction.
Earnings Per Share (EPS) Correlation
Generally, an inverse relationship between the P/E ratio and EPS is observable. Periods of lower EPS, such as those in late 2023 and early 2024, tend to coincide with higher P/E ratios, indicating a potentially overvalued stock relative to earnings. Conversely, higher EPS values generally correspond with lower P/E ratios. However, this relationship is not consistently linear, suggesting other factors influence the P/E ratio.
Overall Trend
While fluctuations are prominent, the P/E ratio demonstrates a tendency to remain within a range of approximately 25 to 49 over the analyzed timeframe. The most recent values suggest a stabilization around the 40-41 range, but continued monitoring is warranted given the historical volatility.

The observed variations in the P/E ratio suggest the company’s valuation is sensitive to changes in both market perception and reported earnings. Further investigation into the underlying drivers of these fluctuations would be beneficial for a more comprehensive understanding of the company’s investment profile.


Price to Operating Profit (P/OP)

Danaher Corp., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating profit (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Operating profit per share = (Operating profitQ4 2025 + Operating profitQ3 2025 + Operating profitQ2 2025 + Operating profitQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


The Price to Operating Profit (P/OP) ratio exhibits considerable fluctuation over the observed period, spanning from April 1, 2022, to December 31, 2025. Initially, the ratio demonstrated a decreasing trend, followed by periods of volatility and subsequent stabilization, then a final increase. A detailed examination reveals distinct phases in the ratio’s behavior.

Initial Decreasing Trend (Apr 1, 2022 – Sep 30, 2022)
From April 1, 2022, to September 30, 2022, the P/OP ratio decreased from 26.48 to 20.71. This decline suggests a potential shift in investor sentiment, possibly reflecting increasing confidence in the company’s operational performance relative to its share price, or broader market conditions impacting valuation multiples. The decrease was not monotonic, with a slight increase from July 1 to September 30.
Volatility and Subsequent Increase (Dec 31, 2022 – Jun 30, 2023)
The ratio experienced significant volatility between December 31, 2022, and June 30, 2023. It initially dropped to a low of 7.03 in December 2022, before rising sharply to 27.01 by June 2023. This period likely reflects substantial changes in market perception, potentially driven by earnings announcements, economic events, or company-specific news. The operating profit per share also decreased during this period, contributing to the initial drop in the P/OP ratio, but the share price decreased at a faster rate.
Peak and Decline (Sep 29, 2023 – Mar 28, 2025)
The P/OP ratio reached its highest point of 39.52 on September 27, 2024, following a period of increases. However, this was followed by a decline to 28.49 by March 28, 2025. This suggests a potential correction in valuation, possibly as investors reassessed the company’s future growth prospects or as operating profit per share remained relatively stable while the share price decreased. The share price experienced a more significant decline than the operating profit per share during this period.
Final Stabilization (Jun 27, 2025 – Dec 31, 2025)
The ratio showed a slight increase from 30.79 in June 2025 to 31.54 in December 2025. This suggests a potential stabilization of investor sentiment, or a re-evaluation of the company’s intrinsic value. The operating profit per share and share price both increased slightly during this period.

Overall, the P/OP ratio demonstrates a dynamic relationship between share price and operating profit per share. The observed fluctuations indicate sensitivity to market conditions and company performance. The ratio’s movement suggests periods of both investor optimism and caution, with a general trend towards higher valuations in the later part of the observed timeframe, followed by a correction.


Price to Sales (P/S)

Danaher Corp., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Sales (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Sales per share = (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


The price-to-sales ratio exhibited considerable fluctuation throughout the observed period, spanning from April 1, 2022, to December 31, 2025. Initial values indicated a relatively stable ratio, followed by a period of increased volatility and a subsequent stabilization towards the end of the timeframe.

Initial Period (Apr 1, 2022 – Dec 31, 2022)
The price-to-sales ratio began at 6.68 and experienced a decline to 5.66 before modestly recovering to 5.79. This suggests a period of initial investor reassessment, potentially influenced by broader market conditions or company-specific news, followed by a slight correction. The share price decreased from $278.24 to $250.11 during this period, while sales per share increased from $41.65 to $43.20.
Volatility and Peak (Mar 31, 2023 – Jun 30, 2023)
A notable increase in the ratio was observed, peaking at 6.77. This coincided with an increase in share price from $231.99 to $255.70, while sales per share decreased from $40.29 to $37.78. This suggests that investor optimism regarding future growth outweighed concerns about current sales performance.
Significant Decline (Jul 1, 2023 – Dec 31, 2023)
The ratio experienced a substantial decline, reaching a low of 5.63 and then increasing to 7.76. This period was marked by a significant decrease in share price from $196.84 to $250.65, and a corresponding decrease in sales per share from $34.99 to $32.30. The large fluctuation indicates a period of considerable uncertainty and potentially a correction in market valuation.
Stabilization and Recent Trend (Jan 1, 2024 – Dec 31, 2025)
Following the volatility, the ratio stabilized, fluctuating between approximately 5.66 and 8.10. The most recent values indicate a slight downward trend, with the ratio ending at 6.02. Share price decreased from $253.11 to $209.19, while sales per share increased from $32.05 to $34.74. This suggests a potential shift in investor sentiment, possibly reflecting concerns about future growth prospects or a reassessment of the company’s valuation relative to its sales.

Overall, the price-to-sales ratio demonstrated a dynamic pattern over the analyzed period. While periods of stability were observed, significant fluctuations suggest sensitivity to market conditions and investor perceptions of the company’s performance and future outlook. The recent trend indicates a potential moderation in valuation, although further observation is needed to confirm this pattern.


Price to Book Value (P/BV)

Danaher Corp., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Danaher stockholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
BVPS = Total Danaher stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Danaher Corp. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-book value (P/BV) ratio exhibits fluctuations over the observed period, generally decreasing before stabilizing and showing a slight increase towards the end of the timeframe. Initial values are relatively high, then decline, followed by a period of relative stability, and a modest upward movement in the most recent quarters.

Initial Period (Apr 1, 2022 – Dec 31, 2022)
The P/BV ratio begins at 4.36 and experiences minimal change through July 1, 2022. A subsequent decline is observed, falling to 3.64 by December 31, 2022. This suggests a decreasing premium investors were willing to pay for each dollar of net asset value during this period.
Declining Trend & Low Point (Mar 31, 2023 – Dec 31, 2024)
The ratio continues to decrease, reaching a low of 2.60 on March 31, 2024. This indicates a significant reduction in the market’s valuation of the company’s net assets relative to its share price. A notable drop to 3.00 is seen on December 31, 2024, before the low point.
Recent Stabilization & Increase (Mar 28, 2025 – Dec 31, 2025)
From March 28, 2025, the P/BV ratio begins to recover, increasing to 3.05 by September 26, 2025, and settling at 2.82 by December 31, 2025. This suggests a renewed investor confidence in the company’s net asset value or a potential correction after the previous declines.
Book Value per Share (BVPS) Trend
Book value per share generally increases throughout the period, from 63.76 to 74.29. This upward trend in BVPS partially offsets the declines observed in the P/BV ratio, indicating that the decrease in the ratio is not solely attributable to a decline in net asset value, but also to changes in market perception of the company’s value.
Share Price Trend
The share price demonstrates considerable volatility. While it initially remains relatively stable, it experiences a significant decrease in September 2023, followed by fluctuations and a general decline before a modest recovery towards the end of the period. This volatility likely contributes to the observed fluctuations in the P/BV ratio.

Overall, the P/BV ratio demonstrates a pattern of decline followed by stabilization and a slight recovery. The interplay between the share price and book value per share is crucial in understanding these movements, suggesting shifts in investor sentiment and market valuation of the company’s net assets.